argenx NV ADR (ARGX)vsCG Oncology, Inc. Common stock (CGON)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
CGON
CG Oncology, Inc. Common stock
$53.72
-4.23%
HEALTHCARE · Cap: $5.25B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 93421% more annual revenue ($4.74B vs $5.07M). ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CGON
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Intrinsic value data unavailable for CGON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 1983.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -17.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : CGON
The strongest argument for CGON centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 1983.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CGON
The primary concerns for CGON are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CGON is a hypergrowth play — different risk/reward profiles.
CGON carries more volatility with a beta of 0.31 — expect wider price swings.
CGON is growing revenue faster at 1983.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 34/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing pioneering cancer therapies, particularly through its lead product, CG0070, an oncolytic virus therapy designed for non-muscle invasive bladder cancer. Committed to addressing significant unmet medical needs in the oncology space, the company is well-positioned to enhance patient outcomes and transform existing treatment paradigms. As CG Oncology progresses through clinical trials and regulatory processes, its proprietary technology platform sets it apart in the competitive oncology landscape, presenting compelling investment opportunities for institutional investors keen on advancing innovations that may substantially influence cancer care.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?